Walleye Trading
EGRX

Walleye Trading’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Walleye Trading’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-360
Closed -$22K – 4710
2019
Q4 		$22K Sell
360
-2,952
-89% -$176K ﹤0.01% 3972
2019
Q3 		$187K Sell
3,312
-2,997
-48% -$169K ﹤0.01% 2970
2019
Q2 		$351K Sell
6,309
-224
-3% -$11.7K ﹤0.01% 2486
2019
Q1 		$330K Buy
6,533
+5,629
+623% +$250K ﹤0.01% 2629
2018
Q4 		$36K Sell
904
-5,345
-86% -$275K ﹤0.01% 4234
2018
Q3 		$433K Buy
6,249
+3,534
+130% +$268K ﹤0.01% 3048
2018
Q2 		$205K Buy
+2,715
New +$171K ﹤0.01% 3626
2017
Q1 		– Sell
-700
Closed -$56K – 5255
2016
Q4 		$56K Sell
700
-3,741
-84% -$272K ﹤0.01% 3573
2016
Q3 		$311K Buy
4,441
+3,479
+362% +$193K ﹤0.01% 2500
2016
Q2 		$37K Buy
+962
New +$40.1K ﹤0.01% 4181
2015
Q4 		– Sell
-400
Closed -$30K – 5778
2015
Q3 		$30K Buy
400
+300
+300% +$25K ﹤0.01% 3851
2015
Q2 		$8K Buy
+100
New +$6.51K ﹤0.01% 4376

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Walleye Trading's EGRX Position: Q1 2020 in Review

Walleye Trading sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2020, closing a stake of 360 shares — an estimated $22K sold.

Walleye Trading first reported a position in EGRX in Q2 2015 and held it in 12 quarters. The position peaked at $433K in Q3 2018. 168 funds tracked by Wall St. Rank hold EGRX as of Q1 2020.

  • Walleye Trading reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Walleye Trading sold 360 Eagle Pharmaceuticals, Inc. shares in Q1 2020, an estimated $22K.
  • Walleye Trading first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 12 quarters.
  • Walleye Trading's Eagle Pharmaceuticals, Inc. position peaked at $433K in Q3 2018.
  • 168 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2020.

Based on Walleye Trading's 13F filing for Q1 2020, filed 15 May 2020.